197 related articles for article (PubMed ID: 19740401)
1. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
Strandell J; Bate A; Hägg S; Edwards IR
Br J Clin Pharmacol; 2009 Sep; 68(3):427-34. PubMed ID: 19740401
[TBL] [Abstract][Full Text] [Related]
2. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Alsheikh-Ali AA; Karas RH
Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins.
Montastruc JL
Br J Clin Pharmacol; 2023 Aug; 89(8):2636-2638. PubMed ID: 37186323
[TBL] [Abstract][Full Text] [Related]
4. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
McAdams M; Staffa J; Dal Pan G
Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
[TBL] [Abstract][Full Text] [Related]
5. Cataracts and statins. A disproportionality analysis using data from VigiBase.
Macías Saint-Gerons D; Bosco Cortez F; Jiménez López G; Castro JL; Tabarés-Seisdedos R
Regul Toxicol Pharmacol; 2019 Dec; 109():104509. PubMed ID: 31669197
[TBL] [Abstract][Full Text] [Related]
6. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
7. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.
Rowan C; Brinker AD; Nourjah P; Chang J; Mosholder A; Barrett JS; Avigan M
Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):301-9. PubMed ID: 19206087
[TBL] [Abstract][Full Text] [Related]
8. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
Edwards IR; Star K; Kiuru A
Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
Ronaldson KJ; O'Shea JM; Boyd IW
Drug Saf; 2006; 29(11):1061-7. PubMed ID: 17061911
[TBL] [Abstract][Full Text] [Related]
10. Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase.
Essers D; Schäublin M; Kullak-Ublick GA; Weiler S
Eur J Clin Pharmacol; 2019 Mar; 75(3):409-416. PubMed ID: 30430215
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
13. Interaction potential between clarithromycin and individual statins-A systematic review.
Hougaard Christensen MM; Bruun Haastrup M; Øhlenschlaeger T; Esbech P; Arnspang Pedersen S; Bach Dunvald AC; Bjerregaard Stage T; Pilsgaard Henriksen D; Thestrup Pedersen AJ
Basic Clin Pharmacol Toxicol; 2020 Apr; 126(4):307-317. PubMed ID: 31628882
[TBL] [Abstract][Full Text] [Related]
14. Statins and immune-mediated necrotizing myopathy: Variability in the risk.
Trenque T; Hadjoudj J; Trenque A; Tralongo F; Martin S; Azzouz B
Therapie; 2024; 79(3):365-370. PubMed ID: 37625939
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological interactions of statins.
Paoletti R; Corsini A; Bellosta S
Atheroscler Suppl; 2002 May; 3(1):35-40. PubMed ID: 12044584
[TBL] [Abstract][Full Text] [Related]
16. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
Xiao M; Li L; Zhu W; Wu F; Wu B
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
[TBL] [Abstract][Full Text] [Related]
17. Statins and erectile dysfunction: results of a case/non-case study using the French Pharmacovigilance System Database.
Do C; Huyghe E; Lapeyre-Mestre M; Montastruc JL; Bagheri H
Drug Saf; 2009; 32(7):591-7. PubMed ID: 19530745
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins).
Igel M; Sudhop T; von Bergmann K
Eur J Clin Pharmacol; 2001 Aug; 57(5):357-64. PubMed ID: 11599653
[TBL] [Abstract][Full Text] [Related]
19. Muscular adverse effects of statins.
Prescrire Int; 2003 Feb; 12(63):21. PubMed ID: 12602397
[No Abstract] [Full Text] [Related]
20. Statin-induced rhabdomyolysis from azithromycin interaction in a patient with heterozygous SLCO1B1 polymorphism.
Burns H; Russell L; Cox ZL
J Clin Pharm Ther; 2021 Jun; 46(3):853-855. PubMed ID: 33277702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
